Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 1.06 · gapped above the open, then crossed back over prior close. High/low 1.10 at 5:00 am ET, 1.03 at 11:45 am ET.
Lineage Cell Therapeutics, Inc. has 9 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either Lineage Cell Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In March 2024, Lineage entered into a sales agreement (the "ATM Sales Agreement") with B. Riley Securities, Inc., as sales agent ("Sales Agent"), under which Lineage may offer and sell its common shares from time to time through an ATM program.”
FILING10-K0001193125-26-093992cik 0000876343
“All of our manufacturing processes, including cell banking and product manufacturing for our cell therapy product candidates, are conducted by our subsidiary, CCN, at its facility in Jerusalem, Israel, and more than two-thirds of our workforce are CCN employees based in that facility.”
FILING10-K0001193125-26-093992cik 0000876343
“In December 2025, CCN accrued a payment obligation to be funded by Lineage due to Hadasit for 21.5% of the $5.0 million received from Roche upon the achievement of the first milestone under the Roche Agreement.”
FILING10-K0001193125-26-093992cik 0000876343
“The $5.5 million increase in collaboration revenue was driven by: (i) the achievement of the first milestone under the Roche Agreement in the amount of $5.0 million whereby $4.6 million was recognized as revenue in 2025; (ii) $2.5 million in revenue from our research collaboration agreement with WDI signed in 2025; (iii) an approximate $0.7 million increase in revenue related to the remaining deferred revenue recognized upon the termination of the license agreement with Immunomic Therapeutics, Inc. in 2025, partially offset by (iv) approximately $2.4 million in lower revenue recognized from deferred revenue under the Roche Agreement.”
FILING10-K0001193125-26-093992cik 0000876343
“The $5.5 million increase in collaboration revenue was driven by: (i) the achievement of the first milestone under the Roche Agreement in the amount of $5.0 million whereby $4.6 million was recognized as revenue in 2025; (ii) $2.5 million in revenue from our research collaboration agreement with WDI signed in 2025; (iii) an approximate $0.7 million increase in revenue related to the remaining deferred revenue recognized upon the termination of the license agreement with Immunomic Therapeutics, Inc. in 2025, partially offset by (iv) approximately $2.4 million in lower revenue recognized from deferred revenue under the Roche Agreement.”
FILING10-K0001193125-26-093992cik 0000876343
“The $5.5 million increase in collaboration revenue was driven by: (i) the achievement of the first milestone under the Roche Agreement in the amount of $5.0 million whereby $4.6 million was recognized as revenue in 2025; (ii) $2.5 million in revenue from our research collaboration agreement with WDI signed in 2025; (iii) an approximate $0.7 million increase in revenue related to the remaining deferred revenue recognized upon the termination of the license agreement with Immunomic Therapeutics, Inc. in 2025, partially offset by (iv) approximately $2.4 million in lower revenue recognized from deferred revenue under the Roche Agreement.”
FILING10-K0001193125-26-093992cik 0000876343
“Lineage and CRT effectuated the option by simultaneously entering into a license agreement (the "CRT License Agreement") pursuant to which Lineage paid a signature fee of £ 1,250,000 (approximately $ 1.6 million based upon exchange rates in effect when the fee was paid).”
FILING10-K0001193125-26-093992cik 0000876343
“To date, through a series of separate grants beginning in 2007, CCN has received a total of $15.4 million from the IIA to support the OpRegen program.”
FILING10-K0001193125-26-093992cik 0000876343
“On March 3, 2026, we entered into an Amended and Restated Non-Exclusive License Agreement (the "A&R WARF License Agreement") with the Wisconsin Alumni Research Foundation ("WARF").”
FILING10-K0001193125-26-093992cik 0000876343
“Lineage continues to make royalty payments to Geron from royalties generated from these patents.”
FILING10-K0001193125-26-093992cik 0000876343
“Independent Registered Public Accounting Firm - Audit Opinion Baker Tilly US, LLP (PCAOB # 23 )”
FILING10-K0001193125-26-093992cik 0000876343
“The clinical development of OPC1 has been supported in part by $14.3 million of funding from CIRM, a state agency established to fund stem cell research and development of new stem cell-based treatments.”
FILING10-K0001193125-26-093992cik 0000876343
“As a result, and subject to the requirements of the Innovation Law, we paid the IIA approximately 24.1% of the upfront payment we received under the Roche Agreement, or approximately $12.1 million, and we are obligated to pay to the IIA approximately 24.1% of any milestone and royalty payments we may receive under the Roche Agreement, up to an aggregate cap on all payments to the IIA, such cap growing over time via interest accrual until paid in full.”
FILING10-K0001193125-26-093992cik 0000876343
Watchlist prices, news filtered to it, and its next report on your desk.
Lineage Cell Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Biological Products, (No Diagnostic Substances)
LCTX (Lineage Cell Therapeutics, Inc.) has 9 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.